Industry Segment: Market Brief | Word Count: 166 Words
Attachment: Cipla

Indian pharmaceuticals major, Cipla Limited, has received approval from the Drug Controller General of India (DCGI) to conduct clinical trials of the influenza drug Favipiravir to examine its efficacy in treating COVID-19. After acquiring the drug production process from the state-run Indian Institute of Chemical Technology (IICT), Cipla sought approval from Indian regulators to launch the experimental drug.

IICT has developed a cost-effective synthetic process for producing Favipiravir, which was originally produced by Fujifilm Toyama Chemical Limited in Japan for treatment of common influenza.